| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 57,877 | 57,843 | ||
| Selling, general and administrative | 26,414 | 32,579 | ||
| Total operating expenses | 84,291 | 90,422 | ||
| Loss from operations | -84,291 | -90,422 | ||
| Research and development incentives | 377 | 420 | ||
| Investment income | 3,696 | 4,714 | ||
| Interest expense on finance lease liability | 518 | 521 | ||
| Interest expense on debt obligations | 1,488 | 1,475 | ||
| Other (expense) income, net | -876 | 591 | ||
| Total other income (expense), net | 1,191 | 3,729 | ||
| Net loss | -83,100 | -86,693 | ||
| Net loss per common share, basic (in dollars per share) | -0.9 | -0.95 | ||
| Net loss per common share, diluted (in dollars per share) | -0.9 | -0.95 | ||
| Weighted average common shares outstanding, basic (in shares) | 91,915,769 | 91,516,199 | ||
| Weighted average common shares outstanding, diluted (in shares) | 91,915,769 | 91,516,199 | ||
Replimune Group, Inc. (REPL)
Replimune Group, Inc. (REPL)